SINTX Technologies
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | <1m | <1m | <1m | <1m | 1.2m | 2.9m | 3.4m |
% growth | 625 % | (14 %) | 2 % | (1 %) | 104 % | 132 % | 20 % |
EBITDA | (5.6m) | (8.6m) | (8.8m) | (10.0m) | (11.5m) | (13.4m) | (14.5m) |
% EBITDA margin | (817 %) | (1455 %) | (1456 %) | (1658 %) | (942 %) | (471 %) | (425 %) |
Profit | (4.8m) | (7.0m) | (8.8m) | (12.0m) | (8.3m) | (11.8m) | (14.1m) |
% profit margin | (696 %) | (1183 %) | (1448 %) | (2003 %) | (674 %) | (414 %) | (412 %) |
EV / revenue | 5.2x | 67.5x | 26.2x | 8.4x | 1.3x | 0.8x | 0.7x |
EV / EBITDA | -0.6x | -4.6x | -1.8x | -0.5x | -0.1x | -0.2x | -0.2x |
R&D budget | 3.4m | 4.8m | 5.9m | 6.5m | 8.7m | - | - |
R&D % of revenue | 493 % | 809 % | 971 % | 1073 % | 711 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $8.4m | Series A | |
N/A | $3.5m | Series B | |
$13.2m | Series D | ||
$10.3m | Series D | ||
$15.0m | Growth Equity VC | ||
N/A | $22.1m | Debt | |
N/A | $30.0m | Debt | |
$21.5m | Debt | ||
N/A | N/A | IPO | |
$26.0m | Post IPO Debt | ||
* | $13.0m | Post IPO Equity | |
N/A | $12.7m | Post IPO Equity | |
N/A | $9.7m | Post IPO Equity | |
* | N/A | $12.0m | Post IPO Equity |
* | $2.0m | Grant | |
* | N/A | $4.0m | Post IPO Equity |
Total Funding | €47.6m |
Recent News about SINTX Technologies
EditSINTX Technologies, Inc., based in Salt Lake City, UT, specializes in developing advanced ceramic materials for medical implants. Founded in 1996 by a material scientist and an orthopedic surgeon, the company initially focused on arthroplasty and later expanded into the spine market. SINTX's core product is silicon nitride, a ceramic material known for its strength, durability, and biocompatibility, making it ideal for use in the human body. The company serves medical device manufacturers and healthcare providers, operating primarily in the orthopedic and spine markets. SINTX generates revenue through the sale of its proprietary ceramic materials and licensing its technology to other medical device companies. The business model is centered on innovation, with a strong emphasis on research and development, as evidenced by its portfolio of 12 issued patents and 19 pending patents. SINTX's state-of-the-art manufacturing facility ensures high-quality production standards, further solidifying its position in the market. The company aims to enhance patient outcomes by providing superior implantable materials that reduce the risk of infection and improve the longevity of medical devices.
Keywords: advanced ceramics, medical implants, silicon nitride, orthopedic, spine market, biocompatibility, FDA clearance, proprietary technology, research and development, high-quality manufacturing.